Contineum Therapeutics, Inc. Class A Common Stock
Price Action
Technical Summary
EMERGING TRENDContineum Therapeutics, Inc. Class A Common Stock is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is moderate (RS Rating: 68), indicating performance broadly in line with the market. Earnings growth of 37% provides fundamental context to the price action. Investors should exercise caution due to high volatility (78% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $12.39 | +21.02% | ABOVE |
| 50 SMA | $13.05 | +14.92% | ABOVE |
| 100 SMA | $13.51 | +11.05% | ABOVE |
| 150 SMA | $12.93 | +16.00% | ABOVE |
| 200 SMA | $12.55 | +19.53% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is CTNM in an uptrend right now?
CTNM has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is CTNM overbought or oversold?
CTNM's RSI (14) is 64. The stock is in neutral territory, neither overbought nor oversold.
Is CTNM outperforming the market?
CTNM has a Relative Strength (RS) Rating of 68 out of 99. CTNM is performing about average compared to the market.
Where is CTNM in its 52-week range?
CTNM is trading at $15.00, which is 92% of its 52-week high ($16.33) and 89% above its 52-week low ($3.72).
How volatile is CTNM?
CTNM has a Beta of 0.75 and 52-week volatility of 78%. It's less volatile than the S&P 500 - generally more stable.